Currently completing a merger with NASDAQ listed MICT, Tingo currently has an Enterprise Value (MRQ) of $3.078 billion and a market cap of $1.279 billion, double what they were yesterday and a seriously out of whack ratio! Tingo's trading results readily justify a market cap of $4 billion which is the company's top management's target this year. My very favourite company Tingo Inc's stock price showed signs of real life yesterday rising more than 120% on significantly increased volume. Alternatively, email editorial-team (at) Stock Price and Chart - OTC:TMNA - TradingView Have feedback on this article? Concerned about the content? Get in touch with us directly. Simply Wall St has no position in any stocks mentioned. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. We aim to bring you long-term focused analysis driven by fundamental data. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. This article by Simply Wall St is general in nature. Here you can find a list of promising dividend stocks with a greater than 2% yield and an upcoming dividend. For example, we've found 4 warning signs for Pfizer that we recommend you consider before investing in the business.Ī common investment mistake is buying the first interesting stock you see. With that in mind though, if the poor dividend characteristics of Pfizer don't faze you, it's worth being mindful of the risks involved with this business. With the way things are shaping up from a dividend perspective, we'd be inclined to steer clear of Pfizer. Fortunately it paid out a lower percentage of its cash flow. Has Pfizer got what it takes to maintain its dividend payments? Earnings per share have not grown all that much, and the company is paying out an uncomfortably high percentage of its income. We're glad to see dividends rising alongside earnings over a number of years, which may be a sign the company intends to share the growth with shareholders. Pfizer has delivered 8.0% dividend growth per year on average over the past 10 years. Very few companies are able to sustainably pay dividends larger than their reported earnings.Ĭlick here to see the company's payout ratio, plus analyst estimates of its future dividends.Īnother key way to measure a company's dividend prospects is by measuring its historical rate of dividend growth. Still, if the company repeatedly paid a dividend greater than its profits, we'd be concerned. It's good to see that while Pfizer's dividends were not covered by profits, at least they are affordable from a cash perspective. Over the last year it paid out 73% of its free cash flow as dividends, within the usual range for most companies. A useful secondary check can be to evaluate whether Pfizer generated enough free cash flow to afford its dividend. Without extenuating circumstances, we'd consider the dividend at risk of a cut. Pfizer distributed an unsustainably high 121% of its profit as dividends to shareholders last year. If a company pays more in dividends than it earned in profit, then the dividend could be unsustainable. As a result, readers should always check whether Pfizer has been able to grow its dividends, or if the dividend might be cut.ĭividends are typically paid from company earnings. If you buy this business for its dividend, you should have an idea of whether Pfizer's dividend is reliable and sustainable. Based on the last year's worth of payments, Pfizer stock has a trailing yield of around 4.0% on the current share price of $38.65. Pfizer's next dividend payment will be US$0.39 per share, and in the last 12 months, the company paid a total of US$1.56 per share. This means that investors who purchase shares on or after the 6th of May will not receive the dividend, which will be paid on the 4th of June. ( NYSE:PFE) is about to trade ex-dividend in the next 4 days.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |